Trial Profile

Monitoring of treatment response under Certolizumab pegol (CZP) in patients with rheumatoid arthritis by ICG-enhanced FOI method Xiralite® as compared to clinical disease activity, laboratory parameters, and musculoskeletal ultrasound (US)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 May 2022 Results published in the Arthritis Research and Therapy
21 Jun 2019 New trial record
15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com